New Hepatitis C Drug Approved: Simeprevir Now Available
This past week, the FDA gave approval to Janssen’s new drug to treat hepatitis C. Simeprevir, commercially know as OLYSIO, is the first new hepatitis C drug since the release of telapravir (Incevik) and boceprevir (Victrelis) in 2011. Simeprevir is a NS3/4A protease inhibitor, used in combination with interferon and ribavirin.
The release of simeprevir marks the beginning of a new wave of direct acting antiviral agents against the hepatitis C virus. Additional drugs are set for FDA approval, including the Gilead drug sofosbuvir in early December 2013.
- See more at: http://blog.texasliver.com/2013/11/new-hepatitis-c-drug-approved-janssens-hepatitis-c-drug-simeprevir-now-available/#sthash.L1iGGqj8.dpuf